Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial.

Journal of biomedicine & biotechnology - 1 Jan 2011

Zwitter Matjaz, Rajer Mirjana, Kovac Viljem, Kern Izidor, Vrankar Martina, Smrdel Uros

Abstract excerpt

BACKGROUND: Intermittent application of chemotherapy and tyrosine kinase inhibitors may avoid antagonism between the two classes of drugs. This hypothesis was tested in a Phase II clinical trial. PATIENTS AND METHODS: Eligible patients were nonsmokers or light smokers, chemo-naïve, with metastatic adenocarcinoma of the lung. TREATMENT: 4 to 6 cycles of gemcitabine 1250 mg/m(2) on days 1 and 4, cisplatin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biopsy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Demography

Share to Disease-Free Survival

Share to Erlotinib Hydrochloride

Share to Quinazolines

Share to Radiography

Share to Radionuclide Imaging

Source

Open in PubMed Open full text

Identifiers

PMID: 21541241
DOI: 10.1155/2011/185646
PMCID: PMC3085288

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Intermittent chemotherapy and erlotinib for nonsmokers or light smokers with advanced adenocarcinoma of the lung: a phase II clinical trial.PMID 21541241Read ↗

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.Semantic proximity Read ↗

Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).Semantic proximity Read ↗

Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.Semantic proximity Read ↗

Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.Semantic proximity Read ↗

Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.Semantic proximity Read ↗

A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors.Semantic proximity Read ↗

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.